Total Funding
50
59
Total FundingSeries D raised
Growth Score
-30 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
25261
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
- Sonny Hsiao: CEO, President & Co-Founder
- Jennifer Wang,: CTO
About the Company
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors,
enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering.
Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.
